Page 85 - CPG มะเร็งปากมดลูก

แนวทางการป?องกันและรกั ษามะเร็งปากมดลูก 79

ECOG (Eastern Cooperative Oncology Group) performance status score:

ECOG score
0 Fully active, able to carry on pre-disease performance without restriction

1 Restricted in physically strenuous activity but ambulatory and able to carry out work
of a light or sedentary nature, e.g., light house work, office work

2 Ambulatory and capable of all selfcare but unable to carry out any work activities.
Up and about more than 50% of waking hours

3 Capable of only limited selfcare, confined to bed or chair more than 50% of
waking hours

4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair

5 Dead

เอกสารอ?างอิง

1. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet
combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2009;
27:4649-55.

2. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel
in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin
Oncol 2004; 22:3113-9.

3. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, et al. A comparison of cisplatin/ paclitaxel and
carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007; 105:299-303.

4. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin
in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015; 33:2129-35.

5. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced
cervical cancer. N Engl J Med 2014 Feb 20; 370(8):734-43.

6 . Monk BJ, Colombo N, Krishnansu Sujata Tewari, Coraline Dubot, M. Valeria Caceres, Hasegawa K, et al. KEYNOTE-826: Final overall survival
results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line
treatment of persistent, recurrent, or metastatic cervical cancer. Journal of clinical oncology. 2023 Jun 1;41(16_suppl):5500–0.

7. Long HJ, 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekinDS, Sorosky J, et al. Randomized phase III trial of cisplatin with or
without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J ClinOncol 2005; 23:4626-33.

8. Brewer CA, Blessing JA, Nagourney RA, McMeekin DS, Lele S, Zweizig SL. Cisplatin plus gemcitabine in previously treated squamous
cell carcinoma of the cervix. Gynecol Oncol 2006; 100:385-8.

9. Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, et al. A phase II trial of carboplatin for recurrent or metastatic
squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990; 39:332-6.

10. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, et al. An update of a phase II study of paclitaxel in advanced or
recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997; 8:657-61.

11. Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for persistent, recurrent, or
metastatic cervical cancer. N Engl J Med 2021;385(20):1856–67.

12. Chung HC, Delord RW. Efficacy and Safety of Pembrolizamab in Previously Treated Advanced Cervical Cancer: Results From the
Phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470–8.